Key facts, as of
As of September 29, 2026, Incyte Corporation (INCY) trades at $123.20, up 46.9% over the past year. Its 52-week range runs from $82.82 to $132.60; the price is 7.1% below that high. It sits 15.6% above its 200-day average of $106.54, the usual sign of a long-term uptrend. Its 30-day volatility is 24.9% annualized, which we rate medium risk. It has a trailing P/E of 15.7.
Cite: Portfolio Terminal, "Incyte Corporation (INCY) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/incy
Where it trades today
trading 81% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- INCY trades at 15.7x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- INCY carries a beta of 0.77, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- INCY is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for INCY come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for INCY. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Incyte Corporation does
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784…
What analysts expect
INCY carries a buy consensus from 23 analysts, with an average price target of $127.96 versus $123.20 today (+3.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
INCY generated $5.82B in trailing revenue (37.7% year over year), with a 27.7% net margin, and $1.18B of free cash flow, supported by $4.50B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $5.14B | $4.77B | $1.34B | $1.29B | $6.59 | $1.33B |
| 2024 | $4.24B | $3.93B | $101.29M | $32.62M | $0.16 | $235.17M |
| 2023 | $3.70B | $3.44B | $655.36M | $597.60M | $2.67 | $449.00M |
| 2022 | $3.39B | $3.19B | $591.63M | $340.66M | $1.53 | $892.11M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
INCY beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 0.3% below its 50-day average and 15.6% above its 200-day.
- RSI at 47 is neither stretched nor washed out.
- The nearest ceiling is $129.84 (+5.4%), the nearest floor $119.51 (-3.0%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is INCY a good buy right now?
Incyte Corporation trades at 15.7x earnings. This is near market average. Current risk level is Medium based on 24.9% volatility.
Does INCY pay dividends?
Incyte Corporation does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is INCY?
With 30-day annualized volatility of 24.9% and beta of 0.77, INCY is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for INCY?
The average analyst price target for Incyte Corporation (INCY) is $127.96 based on 23 analyst estimates, about 3.9% above the current price of $123.20. The published range runs from $86.00 to $155.00.
How much revenue does INCY generate?
Incyte Corporation reported $5.82B in trailing twelve-month revenue. Revenue growth is running at 37.7% year over year. Net margin sits at 27.7%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare INCY with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.